Skip to content- Apr 30, 2026FDA grants Breakthrough Therapy designation for PP-007 in A-LVO strokeThe designation covers PP-007 in Acute Ischemic Stroke due to anterior large vessel occlusion. (opens in a new tab)News
- Feb 4, 2026HEMERA-1 and the HERMES-24 score at ISC 2026Poster: using 24-hour scores to predict 90-day outcomes in HEMERA-1, toward earlier interim analysis in stroke drug trials. (opens in a new tab)Presentation
- Oct 20, 2025HEMERA-1 final results presented at World Stroke Congress 2025Phase 1/2 results presented in Barcelona. (opens in a new tab)Presentation
- Jun 29, 2025Expanded access use of Sanguinate in over 100 cases published in Anesthesia ResearchJahr JS, et al. 2025;2(3):15. (opens in a new tab)Publication
- Feb 5, 2025HEMERA-1 data at International Stroke Conference 2025Preliminary Phase 1 data presented at ISC 2025. (opens in a new tab)Presentation
- Nov 13, 2024PP-007 CMC and clinical data at ISBS 2024Manufacturing and clinical data at the International Symposium on Blood Substitutes. (opens in a new tab)Presentation
- Oct 30, 2024FDA grants Fast Track designation for PP-007Fast Track designation granted during the HEMERA-1 study. (opens in a new tab)News
- Apr 23, 2024HEMERA-1 Phase 1 published in Stroke: Vascular and Interventional NeurologyLinfante I, et al. 2024;4(4):e001246. (opens in a new tab)Publication
- Feb 9, 2023HEMERA-1 Phase 1 at ISC 2023 Late-Breaking ScienceFirst HEMERA-1 data, presented in the Late-Breaking Science session. (opens in a new tab)Presentation
- Dec 14, 2021Canine model of permanent occlusion published in Journal of NeuroInterventional SurgeryChristoforidis GA, et al. 2022;14(12):1253–1257. (opens in a new tab)Publication
